Systemic lupus erythematosus in children;Lupus eritematoso sistémico pediátrico

Anales de Pediatria

Volumn 63, Issue 4, 2005, Pages 321-329

  Stichweh, D ^a   Pascual, V ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

Children; Systemic lupus erythematosus

Indexed keywords

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HORMONAL REGULATION; HUMAN; PATHOGENESIS; REVIEW; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 28144444968     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079833     Document Type: Article

References (88)

1. Font J, Cervera R, Espinosa G, Pallarés L, Ramos-Casals M, Jiménez S, et al. Systemic lupus erythematosus (SLE) in childhood: Analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis. 1998;57:456-9.
2. Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am. 2002;28:561-77.
3. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: A comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995;34:866-72.
4. Iqbal S, Sher MR, Good RA, Cawkwell GD. Diversity in presenting manifestations of systemic lupus erythematosus in children. J Pediatr. 1999;135:500-5.
5. Carreno L, López-Longo FJ, Monteagudo I, Rodríguez-Mahou M, Bascones M, Gonzalez CM, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus. 1999;8:287-92.
6. Benseler SM, Silverman ED. Systemic lupus erythematosus. Pediatr Clin North Am. 2005;52:443-67.
7. Bogdanovic R, Nikolic V, Pasic S, Dimitrijevic J, Lipkovska-Markovic J, Eric-Marinkovic J, et al. Lupus nephritis in childhood: A review of 53 patients followed at a single center. Pediatr Nephrol. 2004;19:36-44.
8. Miettunen PM, Ortiz-Álvarez O, Petty RE, Cimaz R, Malleson PN, Cabral DA, et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J Rheumatol. 2004;31:1650-4.
9. Sibbitt WL Jr, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29:1536-42.
10. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002;46:436-44.
11. Lo JT, Tsai MJ, Wang LH, Huang MT, Yang YH, Lin YT, et al. Sex differences in pediatric systemic lupus erythematosus: A retrospective analysis of 135 cases. J Microbiol Immunol Infect. 1999;32:173-8.
12. Jiménez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2003;25:3-12.
13. Swaak AJ, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L, et al. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis. 1989;48:455-60.
14. Lehman TJ, McCurdy DK, Bernstein BH, King KK, Hanson V. Systemic lupus erythematosus in the first decade of life. Pediatrics. 1989;83:235-9.
15. Vyas S, Hidalgo G, Baqi N, Von Gizyki H, Singh A. Outcome in African-American children of neuropsychiatric lupus and lupus nephritis. Pediatr Nephrol. 2002;17:45-9.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40.
17. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the systemic lupus erythematosus disease activity index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42:1354-60.
18. Bader-Meunier B, Quartier P, Deschenes G, Cochat P, Haddad E, Kone-Paut I, et al. [Childhood-onset systemic lupus erythematosus]. Arch Pediatr. 2003;10:147-57.
19. Wananukul S, Watana D, Pongprasit P. Cutaneous manifestations of childhood systemic lupus erythematosus. Pediatr Dermatol. 1998;15:342-6.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
21. Schmugge M, Revel-Vilk S, Hiraki L, Rand ML, Blanchette VS, Silverman ED. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr. 2003;143:666-9.
22. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999;78:167-75.
23. Campos LM, Kiss MH, D'Amico EA, Silva CA. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus. 2003;12:820-6.
24. Levy DM, Massicotte MP, Harvey E, Hebert D, Silverman ED. Thromboembolism in paediatric lupus patients. Lupus. 2003;12:741-6.
25. Guevara JP, Clark BJ, Athreya BH. Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus. J Rheumatol. 2001;28:854-9.
26. Gazarian M, Feldman BM, Benson LN, Gilday DL, Laxer RM, Silverman ED. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr. 1998;132:109-16.
27. Posadas-Romero C, Torres-Tamayo M, Zamora-González J, Aguilar-Herrera BE, Posadas-Sánchez R, Cardoso-Saldana G, et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum. 2004;50:160-5.
28. Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr Opin Rheumatol. 1999;11:384-92.
29. Lehman TJ. Systemic lupus erythematosus in childhood and adolescence. 5th ed. Baltimore: Williams and Wilkins; 1997.
30. Lee T, Von Scheven E, Sandborg C. Systemic lupus erythematosus and antiphospholipid syndrome in children and adolescents. Curr Opin Rheumatol. 2001;13:415-21.
31. Trapani S, Camiciottoli G, Ermini M, Castellani W, Falcini F. Pulmonary involvement in juvenile systemic lupus erythematosus: A study on lung function in patients asymptomatic for respiratory disease. Lupus. 1998;7:545-50.
32. Ciftci E, Yalcinkaya F, Ince E, Ekim M, Ileri M, Orgerin Z, et al. Pulmonary involvement in childhood-onset systemic lupus erythematosus: A report of five cases. Rheumatology (Oxford). 2004;43:587-91.
33. Bakkaloglu A. Lupus nephropathy in children. Nephrol Dial Transplant. 2001;16 Suppl 6:126-8.
34. Sandborg CI. Childhood systemic lupus erythematosus and neonatal lupus syndrome. Curr Opin Rheumatol. 1998;10:481-7.
35. Zappitelli M, Duffy C, Bernard C, Scuccimarri R, Watanabe Duffy K, Kagan R, et al. Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr Nephrol. 2004;19:503-10.
36. Hill GS, Delahousse M, Nochy D, Tomkiewicz E, Remy P, Mignon F, et al. A new morphologice index for the evaluation of renal biopsies in lupus nephritis. Kidney Int. 2000;58:1160-73.
37. Yang LY, Chen WP, Lin CY. Lupus nephritis in children-a review of 167 patients. Pediatrics. 1994;94:335-40.
38. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
39. Mageed RA, Prud'homme GJ. Immunopathology and the gene therapy of lupus. Gene Ther. 2003;10:861-74.
40. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100:3019-26.
41. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004;6:R295-302.
42. Hochberg MC. Prevalence of systemic lupus erythematosus in England and Wales, 1981-2. Ann Rheum Dis. 1987;46:664-6.
43. Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med. 1975;59:533-52.
44. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35:311-8.
45. Kelly JA, Moser KL, Harley JB. The genetics of systemic lupus erythematosus: Putting the pieces together. Genes Immun. 2002;3 Suppl 1:71-85.
46. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 2001;15:397-408.
47. Sestak AL, Nath SK, Harley JB. Genetics of systemic lupus erythematosus: How far have we come? Rheum Dis Clin North Am. 2005;31:223-44.
48. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-70.
49. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004;22:431-56.
50. Goto M, Tanimoto K, Horiuchi Y. Natural cell mediated cytotoxicity in systemic lupus erythematosus: Suppression by antilymphocyte antibody. Arthritis Rheum. 1980;23:1274-81.
51. Kyttaris VC, Tsokos GC. T lymphocytes in systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2004;16:548-52.
52. Tsokos GC. Systemic lupus erythematosus. A disease with a complex pathogenesis. Lancet. 2001;358 Suppl:65.
53. Inghirami G, Simon J, Balow JE, Tsokos GC. Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol. 1988;6:269-76.
54. Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med. 2004;10:411-5.
55. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33.
56. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol. 2001;167:2361-9.
57. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374-7.
58. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. En prensa. J Exp Med. 2005.
59. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540-3.
60. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711-23.
61. Winoto A, Littman DR. Nuclear hormone receptors in T lymphocytes. Cell. 2002;109 Suppl:57-66.
62. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179:1317-30.
63. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
64. McMurray RW, Suwannaroj S, Ndebele K, Jenkins JK. Differential effects of sex steroids on T and B cells: Modulation of cell cycle phase distribution, apoptosis and bcl-2 protein levels. Pathobiology. 2001;69:44-58.
65. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens are generated during apoptosis. J Exp Med. 1995;181:1557-61.
66. Nakamura N, Ban T, Yamaji K, Yoneda Y, Wada Y. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest. 1998;101:1951-9.
67. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001;28:780-5.
68. Austin HA 3rd, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-9.
69. Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velázquez MR, et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis Rheum. 2003;49:501-7.
70. Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997;24:1608-14.
71. Hochberg MC, Sutton JD. Physical disability and psychosocial dysfunction in systemic lupus erythematosus. J Rheumatol. 1988;15:959-64.
72. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2003;48:442-54.
73. Wallace DJ, Tumlin JA, LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus. 2004;13:323-7.
74. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-7.
75. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580-90.
76. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719-27.
77. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:95-101.
78. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251-8.
79. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253-65.
80. Furie R. Safety and pharmacodynamic results of a phase I single and double dose-escalation study of Lymphostat-B in SLE patients. Arthritis Rheum. 2003;48 Suppl:377.
81. Moosig F, Zeuner R, Renk C, Schroder JO. IL-1RA in refractory systemic lupus erythematosus. Lupus. 2004;13:605-6.
82. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64:630-3.
83. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995;181:839-44.
84. Wulffraat NM, Sanders EA, Kamphuis SS, Rijkers GT, Kuis W, Lilien M, et al. Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus. Arthritis Rheum. 2001;44:728-31.
85. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: Results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol. 2005;141:1-9.
86. Gratwohl A, Passweg J, Bocelli-Tyndall C, Fassas A, Van Laar JM, Farge D, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2005;35:869-79.
87. Hirashima M, Fukazawa T, Abe K, Morita Y, Kusaoi M, Hashimoto H. Expression and activity analyses of CTLA4 in peripheral blood lymphocytes in systemic lupus erythematosus patients. Lupus. 2004;13:24-31.
88. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus. 2005;14:197-203.